Skip to main content
. 2022 Sep 12;28(10):2155–2161. doi: 10.1038/s41591-022-01962-5

Fig. 4. scRNA-seq analysis of selected genes expressed in tumor tissue from 15 patients following treatment with neoadjuvant atezolizumab.

Fig. 4

a, The expression of different NK cell surface receptors was determined by scRNA-seq. b, Tumor samples collected at resection were classified into three groups of five samples each on the basis of the percentage of viable tumor cells by pathological analysis: low (≤25% viable tumor cells), middle (26–50%) and high (>50%). Dot size represents the percentage of NK cells in the group expressing the gene. Color represents the scaled average normalized expression. NK cells were downsampled to have the same number of cells in each group. ILT2 is also known as LILRB1, ILT4 as LILRB2, KIR2DL1 as CD158a, NKG2D as CD314 and KLRK1 and PD-L1 as CD274. CD, cluster of differentiation; CMP, common myeloid progenitor; ILT, immunoglobulin-like transcript; KIR2DL1, killer cell immunoglobulin-like receptor DL1; LILRB, leukocyte immunoglobulin-like receptor subfamily B; NKG2, natural killer group protein 2.